Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2008

View Archived Issues

Nucleoside reverse transcriptase inhibitor active in mouse AIDS model

Antiretroviral compound may have distinct mechanism of action

Reduction of CSF biomarkers with PBT-2 treatment in phase II study

MyD88 deficiency associated with rare pyogenic bacterial infections in children

Vertex offers Q2 overview

Cannabinoid receptor 1 identified as colorectal cancer target

Oxycyte in development as gel for surface wounds

Acrux and KV sign expanded agreement for Evamist and other products

Peregrine initiates patient screening and dosing in phase II trial of bavituximab

PhytoMedical acquires worldwide license rights to Dartmouth's novel anticancer compounds

Starpharma initiates clinical trial to measure level of antiviral activity retained by VivaGel

Sanofi-aventis exercises option for expanded access to ImmunoGen's TAP technology

FDA accepts Pain Therapeutics' NDA for Remoxy and grants priority review

SF-1019 approved in Malaysia

NCI initiates enrollment in phase II clinical trial of Reolysin

Shire: Q2 update

MedImmune initiates phase IIa clinical trial of Medarex's MEDI-545 in SLE

Canopus Biopharma reports positive results from mouse study of StatC in H5N1, H1N1 and H3N2

Cerus is granted CE mark for Intercept in treatment of previously frozen plasma

New agents for metabolic disorders described in recent patents

New analgesic agents revealed in recent patents

Recent patents describe novel agents for asthma, allergy, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...